Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

Cover Page

Cite item

Full Text

Abstract

Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically polymorphic mutation in HIV-1 sub-subtype A6, which is the most widespread virus variant in Russia.

Materials and methods. The European EuResist (EIDB) database was queried to form two equivalent groups of patients: group 1 ‒ patients with A62V at baseline treated with TDF or TAF on the first-line therapy, group 2 ‒ patients without A62V at baseline treated with TDF or TAF on the first-line therapy. Each group included 23 patients.

Results. There was no statistical difference between the two groups in virologic efficacy in 4, 12, and 24 weeks after the start of antiretroviral therapy (ART) and in the frequency of virologic failures.

Conclusion. This study has some limitations, and the exact role of A62V in the efficacy of the first-line ART based on tenofovir deserves further investigation.

About the authors

Ekaterina N. Ozhmegova

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Author for correspondence.
Email: ozhmegova.eka@gmail.com
ORCID iD: 0000-0002-3110-0843

PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Anna I. Kuznetsova

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: a-myznikova@list.ru

PhD, Head of the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Aleksey V. Lebedev

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: lebedevalesha236@gmail.com
ORCID iD: 0000-0001-6787-9345

PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Anastasia A. Antonova

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: anastaseika95@mail.ru
ORCID iD: 0000-0002-9180-9846

PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Kristina V. Kim

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: kimsya99@gmail.com
ORCID iD: 0000-0002-4150-2280

Junior Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Yana M. Munchak

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: yanka.zabavnaya@mail.ru
ORCID iD: 0000-0002-4792-8928

Junior Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Alexander S. Tumanov

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: desep@mail.ru
ORCID iD: 0000-0002-6221-5678

Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

Elena V. Kazennova

National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health

Email: kazennova@rambler.ru
ORCID iD: 0000-0002-7912-4270

D. Sc. (Biology), Leading Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky

Russian Federation, Moscow

References

  1. Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu
  2. Wensing A.M., Calvez V., Ceccherini-Silberstein F., Charpentier C., Günthard H.F., Paredes R., et al. 2022 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 2022; 30(4): 559–74.
  3. Maldonado J.O., Mansky L.M. The HIV-1 reverse transcriptase A62V mutation influences replication fidelity and viral fitness in the context of multi-drug-resistant mutations. Viruses. 2018; 10(7): 376. DOI: https://doi.org/10.3390/v10070376
  4. Svarovskaia E.S., Feng J.Y., Margot N.A., Myrick F., Goodman D., Ly J.K., et al. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 2008; 48(4): 428–36. DOI: https://doi.org/10.1097/QAI.0b013e31817bbe93
  5. Rhee S.Y., Varghese V., Holmes S.P., Van Zyl G.U., Steegen K., Boyd M.A., et al. Mutational correlates of virological failure in individuals receiving a WHO-recommended Tenofovir-containing first-line regimen: an international collaboration. EBioMedicine. 2017; 18: 225–35. DOI: https://doi.org/10.1016/j.ebiom.2017.03.024
  6. Wagner T., Zuckerman N.S., Halperin T., Chemtob D., Levy I., Elbirt D., et al. Epidemiology and transmitted HIV-1 drug resistance among treatment-naive individuals in Israel, 2010–2018. Viruses. 2021; 14(1): 71. DOI: https://doi.org/10.3390/v14010071
  7. Zhukova A., Dunn D., Gascuel O. Modeling drug resistance emergence and transmission in HIV-1 in the UK. Viruses. 2023; 15(6): 1244. DOI: https://doi.org/10.3390/v15061244
  8. Kazennova E.V., Lapovok I.A., Laga V.Y., Vasilyev A.V., Bobkova M.R. Natural polymorphisms of HIV-1 IDU-A variant pol gene. VICh-infektsiya i immunosupressii. 2012; 4(4): 44–51. EDN: https://elibrary.ru/pjowuj (in Russian)
  9. Kirichenko A.A., Kireev D.E., Shlykova A.V., Lopatukhin A.E., Lapovok I.A., Saleeva D.V., et al. HIV-1 drug resistance in patients with virological inefficiency on ART in Russia in 2013–2021. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy. 2021; 11(3): 53–62. DOI: https://doi.org/10.18565/epidem.2021.11.3.53-62 EDN: https://elibrary.ru/uqiuni (in Russian)
  10. Ministry of Health of the Russian Federation. Clinical Guidelines «HIV Infection in Adults»; 2020. Available at: http://rushiv.ru/wp-content/uploads/2022/11/KR79.pdf (in Russian)
  11. Clinicalinfo. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
  12. Bbosa N., Kaleebu P., Ssemwanga D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS. 2019; 14(3): 153–60. DOI: https://doi.org/10.1097/coh.0000000000000534
  13. Kirichenko A., Lapovok I., Baryshev P., van de Vijver D., van Kampen J.J.A., Boucher C.A.B., et al. Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs. Viruses. 2020; 12(8): 838. DOI: https://doi.org/10.3390/v12080838
  14. Kuznetsova A., Lebedev A., Gromov K., Kazennova E., Zazzi M., Incardona F., et al. Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line ART regimens using rilpivirine in human immunodeficiency virus-infected patients. Clin. Case Rep. 2022; 10(2): e05373. DOI: https://doi.org/10.1002/ccr3.5373
  15. Sukhanova A.L., Rudinskii N.I., Bogoslovskaya E.V., Kruglova A.I., Bashkirova L.Yu., Tsyganova G.M., et al. Polymorphism of the genome region coding for protease and reverse transcriptase in HIV type 1 subtype a variants prevailing in CIS countries. Molekulyarnaya biologiya. 2005; 39(6): 934–41. DOI: https://doi.org/10.1007/s11008-005-0115-8 EDN: https://elibrary.ru/ljarmp
  16. Kolomeets A.N., Varghese V., Lemey P., Bobkova M.R., Shafer R.W. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. Aids. 2014; 28(17): F1–8. DOI: https://doi.org/10.1097/qad.0000000000000485
  17. Kirichenko A., Kireev D., Lopatukhin A., Murzakova A., Lapovok I., Saleeva D., et al. Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries. PLoS One. 2022; 17(1): e0257731. DOI: https://doi.org/10.1371/journal.pone.0257731
  18. Shchemelev A.N., Ostankova Yu.V., Valutite D.E., Serikova E.N., Zueva E.B., Semenov A.V., et al. Risk assessment of first-line treatment failure in untreated HIV patients in Northwestern federal district of the Russian Federation. Infektsiya i immunitet. 2023; 13(2): 302–8. DOI: https://doi.org/10.15789/2220-7619-RAO-2122 EDN: https://elibrary.ru/ciclmu (in Russian)
  19. Costa B., Vale N. Efavirenz: history, development and future. Biomolecules. 2022; 13(1): 88. DOI: https://doi.org/10.3390/biom13010088
  20. Lv Z., Chu Y., Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl.). 2015; 7: 95–104. DOI: https://doi.org/10.2147/hiv.S79956
  21. Salvaña E.M.T., Dungca N.T., Arevalo G., Li K., Francisco C., Penalosa C., et al. HIV-1 subtype shift in the Philippines is associated with high transmitted drug resistance, high viral loads, and fast immunologic decline. Int. J. Infect. Dis. 2022; 122: 936–43. DOI: https://doi.org/10.1016/j.ijid.2022.06.048

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. The dynamics of VLs during the follow-up period

Download (542KB)
Indexing metadata

Copyright (c) 2024 Ozhmegova E.N., Kuznetsova A.I., Lebedev A.V., Antonova A.A., Kim K.V., Munchak Y.M., Tumanov A.S., Kazennova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies